An Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Health Care Team Outcomes of Selective Beta - 1 Blockers
Description
Among the cardio-selective beta-1-blockers are nebivolol, metoprolol, acebutolol, esmolol, betaxolol, bisoprolol, and atenolol. Heart failure, post-myocardial infarction, hypertension, chronic stable angina, and decreased left ventricular function following a recent myocardial infarction are among the conditions for which beta-1-selective blockers are FDA-approved. Preventing migraines, treating arrhythmias, reducing tremors, and treating the symptoms of anxiety disorders are among the non-FDA-approved use. Reduced morbidity and mortality following myocardial infarction is associated with their use. Beta-1 blocker therapy lowers the risk of congestive heart failure, coronary artery disease, and stroke. In order for providers to guide patient therapy regarding the treatment of indicated disorders as part of the interprofessional team, this activity provides information on the indications, mechanisms of action, administration techniques, significant adverse effects, contraindications, and monitoring of selective beta-1 antagonists. It also provides a foundation for optimal utilization based on current knowledge.
Files
An Indications, Mechanism of Action, Administration -HBRP Publication.pdf
Files
(384.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:77f2e262893db9e9a361854b3f4be85b
|
384.9 kB | Preview Download |
Additional details
References
- 1. Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013 Apr;31(2):76-83. [PubMed]
- 2. Farzam K, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 22, 2023. Beta Blockers. [PubMed]
- 3. Alhayek S, Preuss CV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 14, 2023. Beta 1 Receptors. [PubMed]
- 4. Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. J Clin Pharmacol. 1988 Jan;28(1):6-21. [PubMed]
- 5. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009 May 21;459(7245):356-63. [PMC free article] [PubMed]
- 6. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature. 2008 Jul 24;454(7203):486-91. [PMC free article] [PubMed]
- 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 3, 2018. Beta Adrenergic Blocking Agents. [PubMed]
- 8. Mathew P, Thoppil D. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 26, 2022. Hypoglycemia. [PubMed]
- 9. White JR, Campbell RK. Dangerous and common drug interactions in patients with diabetes mellitus. Endocrinol Metab Clin North Am. 2000 Dec;29(4):789-802. [PubMed]
- 10. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002 Nov 05;137(9):715-25. [PubMed]